{
  "report_rows": [
    {
      "kpi": "Pro forma adjusted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$1.24 vs. cons $1.22",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Pro forma revenue",
      "prediction": "IN-LINE",
      "answer": "pred ~$705M vs. cons $704M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Pro forma adjusted operating margin",
      "prediction": "IN-LINE",
      "answer": "pred ~27.0% vs. cons/guide 27.0%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 pro forma adjusted EPS guidance",
      "prediction": "BETTER",
      "answer": "guide ~$5.25-$5.35 vs. cons $5.25 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 pro forma revenue guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~$2.81-$2.84B vs. cons $2.82B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q3 2026 pro forma adjusted operating margin",
      "prediction": "UNCHANGED",
      "answer": "guide ~29% vs. cons ~28.5-29% (Q3 2026)",
      "confidence": "LOW"
    },
    {
      "kpi": "China Immunodiagnostics definitive agreement status",
      "prediction": "UNKNOWN",
      "answer": "guide ~pending/no confirmed signing vs. cons expectation of Q2 signing (Q2 2026)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": -1.2,
  "day1_confidence": "LOW",
  "day5_residual_pct": -1.8,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "Stock has rallied 30%+ since Q1 and sits near consensus price targets, leaving little cushion; a merely in-line/modest-beat print with guidance simply reiterated (not meaningfully raised) and an unresolved China IDx definitive-agreement timeline (flagged as a name-defining open item) removes the catalyst needed to sustain the run. With Q3 margin (29%) and H2 organic acceleration still to be proven, sell-side is likely to trim near-term estimates or hold flat rather than raise out-period numbers, so any initial soft reaction should see modest follow-through over the week rather than a snap-back, absent a surprise on the China IDx deal or a explicit FY raise.",
  "day5_confidence": "LOW"
}